This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Float Your Boat in a Biotech Moat

This column was originally published on RealMoney on Aug. 1 at 11:40 a.m. EDT. It's being republished as a bonus for TheStreet.com readers.

We're all looking for companies that can exhibit phenomenal long-term growth while maintaining high profitability. Trouble is, that isn't easy, especially in technology. The majority of tech companies are like professional athletes: extremely prolific, but only for short periods of time.

Long-term profit generation and stock appreciation depend on margin sustainability, and the only way to maintain margins is high barriers to entry for competitors. But technology is always changing and competition is intense, so it's unusual to find a technology in which the barriers to entry are high enough to prevent competition from eroding margins -- or a new technology from completely supplanting it.

In the past, the most reliably profitable companies were pharmaceuticals, where drugs were protected by patent. That's changing quickly as development costs are exploding and generic competition intensifying. The next most impressive profit generators are anticompetitive monopolies like Microsoft or Intel. We are slowly legislating away those situations.

That leaves us looking for great innovators with new technology, maybe a touch of prohibitive patent protection, some impressive execution, and maybe just a little undisclosed technological know-how for some breathing room. Let's examine two next-generation technology companies, Crucell (CRXL) and Given Imaging (GIVN), that may have the moats to float our financial boats.

Crucell is a Dutch biotech company that develops vaccines and antibodies based on its proprietary human cell line, PER.C6. Until recently, it was more of a development-stage company with several internal vaccine development programs and an impressive list of partnerships with top-line big pharma and biotech companies like Merck, GlaxoSmithKline and Chiron, now part of Novartis. Its recent acquisition of Swiss vaccine company Berna Biotech makes it a full-fledged vaccine provider.

The reason this company offers a significant long-term opportunity is its immortal self-replicating human cell line, which is a cell culture that will grow indefinitely given the appropriate medium and conditions. PER.C6 can be used for the discovery and manufacture of vaccines and antibodies, and it is the reason much larger companies have taken notice and forged partnerships with the company.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs